Braidwell LP Neurocrine Biosciences Inc Transaction History

Braidwell LP

$1.63 Billion
Q1 2025

A detailed history of Braidwell LP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Braidwell LP holds 1,191,925 shares of NBIX stock, worth $158 Million. This represents 8.09% of its overall portfolio holdings.

Number of Shares

1,191,925

Previous 901,790 32.17%

Holding current value

$158 Million

Previous $123 Million 7.09%

% of portfolio

8.09%

Previous 6.9%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$107.22 - $153.29 $31.1 Million - $44.5 Million	290,135 Added 32.17%	1,191,925 $132 Million
Q4 2024 Feb 14, 2025	SELL	$111.62 - $139.44 $1.77 Million - $2.21 Million	-15,884 Reduced 1.73%	901,790 $123 Million
Q3 2024 Nov 14, 2024	BUY	$114.58 - $153.15 $18.2 Million - $24.3 Million	158,665 Added 20.9%	917,674 $106 Billion
Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $3.77 Million - $4.12 Million	28,800 Added 3.94%	759,009 $104 Billion
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $1.96 Million - $2.16 Million	15,000 Added 2.1%	730,209 $101 Billion
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $26.8 Million - $33.6 Million	-252,815 Reduced 26.12%	715,209 $94.2 Billion
Q3 2023 Nov 14, 2023	BUY	$94.02 - $117.1 $3.26 Million - $4.06 Million	34,662 Added 3.71%	968,024 $109 Billion
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $14.9 Million - $17.5 Million	166,562 Added 21.72%	933,362 $88 Billion
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $72.2 Million - $94.3 Million	766,800 New	766,800 $77.6 Billion

Others Institutions Holding NBIX

# of Institutions

650

Shares Held

96.9M

Call Options Held

749K

Put Options Held

553K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.6B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Braidwell LP, based on Form 13F filings with the SEC.

News

Stay updated on Braidwell LP with notifications on news.

Account